✦ LIBER ✦

A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

✍ Scribed by Koutsky, Laura A.; Ault, Kevin A.; Wheeler, Cosette M.; Brown, Darron R.; Barr, Eliav; Alvarez, Frances B.; Chiacchierini, Lisa M.; Jansen, Kathrin U.

Book ID: 121705631
Publisher: Massachusetts Medical Society
Year: 2002
Tongue: English
Weight: 170 KB
Volume: 347
Category: Article
ISSN: 0096-6762
DOI: 10.1056/nejmoa020586

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of a vaccine t

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects

✍ S. KANG; K.H. KIM; Y.T. KIM; Y.T. KIM; J.H. KIM; Y.S. SONG; S.H. SHIN; H.S. RYU; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Safety and immunogenicity of a vaccine t

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

✍ Rongcheng Li; Yanping Li; David Radley; Youping Liu; Teng Huang; Heather L. Sing 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 350 KB

Efficacy of a bivalent L1 virus-like par

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

✍ Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 185 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

## Background: Effective vaccination against hpv 16 and hpv 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent hpv-16/18 l1 virus-like part

Efficacy of a prophylactic adjuvanted bi

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

✍ Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Coset 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 151 KB